PET Studies

Imanet has insights into the challenges of PET in drug trials and experience providing solutions using PET imaging in clinical trials worldwide.

PK biomarkers

• Radiolabeled drug candidate studies

PD biomarkers

• Studies of drug candidate interaction with target system using a target-specific PET tracer
• Studies of drug effect on downstream systems using a PET tracer imaging physiology

Key components of Imanet’s PET services

• Expert advice on study design and data interpretation
• Access to an extensive bank of PET tracers
• Excellence in radiochemical labeling
• Rapid response to requests and reliable delivery to deadlines
• Compliance with local and national regulatory standards
• Project management of both single-center and multi-center studies
• Direct links with well-established CROs and clinical centers
• Full confidentiality

Our comprehensive imaging trial services include the following:

• Protocol development and integrated electronic CRF production
• Imaging site setup including safety evaluations, imagining procedures and hands-on training of personnel and alignment to local practices, ensuring the right combination of clinical expertise, patient population and imaging equipment
• Submissions to regulatory authorities and ethics boards including documentation ensuring regulatory compliance with the Imaging Manual, Image Quality Control Manual and Image Transfer Manual
• Image transfer, automated anonymization, comprehensive quality checks through effective real-time quality control and site feedback to reduce the number of non-evaluable image datasets
• Qualitative and quantitative analysis of results (safety, dosimetry and efficacy)
• Blinded reads, statistical analysis and endpoint reporting

To contact Imanet about the research services we provide, please e-mail imanet@ge.com.